Kanaly Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Kanaly Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$428K	Sell	3,498 -1,121	-24%	-$137K	0.09%	91
2016 Q3	$566K	Sell	4,619 -204	-4%	-$26.3K	0.12%	91
2016 Q2	$563K	Sell	4,823 -172	-3%	-$24.4K	0.11%	91
2016 Q1	$695K	Sell	4,995 -1	-0%	-$147	0.14%	80
2015 Q4	$953K	Sell	4,996 -122	-2%	-$21.3K	0.2%	66
2015 Q3	$800K	Sell	5,118 -77	-1%	-$14K	0.18%	69
2015 Q2	$939K	Buy	5,195 +1,363	+36%	+$235K	0.19%	66
2015 Q1	$664K	Buy	3,832 +3,752	+4,690%	+$679K	0.13%	90
2014 Q4	$15K	Buy	80 +20	+33%	+$3.71K	﹤0.01%	410
2014 Q3	$10K	Hold	60	–	–	﹤0.01%	461
2014 Q2	$9K	Buy	60 +41	+216%	+$6.47K	﹤0.01%	489
2014 Q1	$3K	Buy	+19	New	+$3.02K	﹤0.01%	618

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Kanaly Trust's ALXN Position: Q4 2016 in Review

Kanaly Trust reduced its Alexion Pharmaceuticals (ALXN) stake by 24% in Q4 2016, selling an estimated $137K and leaving 3,498 shares worth $428K. The position accounts for 0.09% of the portfolio, ranked #91.

Kanaly Trust first reported a position in ALXN in Q1 2014 and has held it in 12 quarters since. The position peaked at $953K in Q4 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Kanaly Trust held 3,498 shares of Alexion Pharmaceuticals worth $428K as of Q4 2016.
Kanaly Trust sold 1,121 Alexion Pharmaceuticals shares in Q4 2016, an estimated $137K.
Alexion Pharmaceuticals made up 0.09% of Kanaly Trust's portfolio in Q4 2016, its #91 holding.
Kanaly Trust first reported a position in Alexion Pharmaceuticals in Q1 2014 and has held it in 12 quarters since.
Kanaly Trust's Alexion Pharmaceuticals position peaked at $953K in Q4 2015.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.